Monitoring the Effectiveness and Safety of Antihypertensive Therapy With a Fixed-Dose Combination of Perindopril and Amlodipine in Patients With Uncontrolled Essential Hypertension
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bosnalijek D.D
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients older than 18 and younger than 75 years
Patients with essential hypertension with blood pressure values ≥ 140/90 mmHg
You may not be if
Hypersensitivity to the components of the drug
Positive history of angioneurotic edema
Pregnancy
Breastfeeding
Patients who are planning to become pregnant in the near future
Significant bilateral renal artery stenosis or renal artery stenosis in one functional kidney
Severe hypotension
Obstruction of the outflow tract of the left ventricle of the heart (eg, high-grade aortic stenosis)
Hemodynamically unstable heart failure after acute myocardial infarction
Simultaneous use with drugs containing aliskiren in patients with diabetes mellitus or with renal impairment (GFR \<60 ml/min/1.73 m2)
Simultaneous use with sacubitril/valsartan
Patients with primary hyperaldosteronism
Severe liver damage
Withdrawal Criteria:
Deterioration of the clinical picture of the underlying disease that requires discontinuation of the study therapy and the introduction of additional diuretic therapy with indapamide and/or hospitalization
Development of serious adverse events requiring discontinuation of therapy
Occurrence of pregnancy
Development of another disease that affects the course of research
Clareo Health | Monitoring the Effectiveness and Safety of Antihypertensive Therapy With a Fixed-Dose Combination of Perindopril and Amlodipine in Patients With Uncontrolled Essential Hypertension
